|
|
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies
|
|
|
|
|
نویسنده
|
Kamitsuji Shigeo ,Matsuda Takashi ,Nishimura Koichi ,Endo Seiko ,Wada Chisa ,Watanabe Kenji ,Hasegawa Koichi ,Hishigaki Haretsugu ,Masuda Masatoshi ,Kuwahara Yusuke ,Tsuritani Katsuki ,Sugiura Kenkichi ,Kubota Tomoko ,Miyoshi Shinji ,Okada Kinya ,Nakazono Kazuyuki ,Sugaya Yuki ,Yang Woosung ,Sawamoto Taiji ,Uchida Wataru ,Shinagawa Akira ,Fujiwara Tsutomu ,Yamada Hisaharu ,Suematsu Koji ,Tsutsui Naohisa ,Kamatani Naoyuki ,Liou Shyh-Yuh
|
منبع
|
journal of human genetics - 2015 - دوره : 60 - شماره : 6 - صفحه:319 -326
|
چکیده
|
Japan pharmacogenomics data science consortium (jpdsc) has assembled a database for conducting pharmacogenomics (pgx) studies in japanese subjects. the database contains the genotypes of 2.5 million single-nucleotide polymorphisms (snps) and 5 human leukocyte antigen loci from 2994 japanese healthy volunteers, as well as 121 kinds of clinical information, including self-reports, physiological data, hematological data and biochemical data. in this article, the reliability of our data was evaluated by principal component analysis (pca) and association analysis for hematological and biochemical traits by using genome-wide snp data. pca of the snps showed that all the samples were collected from the japanese population and that the samples were separated into two major clusters by birthplace, okinawa and other than okinawa, as had been previously reported. among 87 snps that have been reported to be associated with 18 hematological and biochemical traits in genome-wide association studies (gwas), the associations of 56 snps were replicated using our data base. statistical power simulations showed that the sample size of the jpdsc control database is large enough to detect genetic markers having a relatively strong association even when the case sample size is small. the jpdsc database will be useful as control data for conducting pgx studies to explore genetic markers to improve the safety and efficacy of drugs either during clinical development or in post-marketing.
|
|
|
آدرس
|
StaGen, Japan, Astellas Pharma, Japan, Astellas Pharma, Japan, Daiichi Sankyo, Japan, Daiichi Sankyo, Japan, Daiichi Sankyo, Japan, Otsuka Pharmaceutical, Japan, Otsuka Pharmaceutical, Japan, Otsuka Pharmaceutical, Japan, Taisho Pharmaceutical, Japan, Taisho Pharmaceutical, Japan, Takeda Pharmaceutical Company Limited, Japan, Mitsubishi Tanabe Pharma Corporation, Japan, Mitsubishi Tanabe Pharma Corporation, Japan, Mitsubishi Tanabe Pharma Corporation, Japan, StaGen, Japan, StaGen, Japan, StaGen, Japan, Astellas Pharma, Japan, Astellas Pharma, Japan, Daiichi Sankyo, Japan, Otsuka Pharmaceutical, Japan, Taisho Pharmaceutical, Japan, Taisho Pharmaceutical, Japan, Mitsubishi Tanabe Pharma Corporation, Japan, StaGen, Japan, Takeda Pharmaceutical Company Limited, Japan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|